Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6DN12
UPID:
MCTP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q6DN12; A2RRC2; C6G483; C6G484; Q49AB0; Q8TAX2; Q9NUS2; Q9NUW7
Background:
The Multiple C2 and transmembrane domain-containing protein 2, identified by the accession number Q6DN12, is implicated in the intricate process of cardiac outflow tract development. This protein's unique structure, featuring multiple C2 domains and transmembrane regions, suggests a specialized role in cellular functions related to heart development.
Therapeutic significance:
Understanding the role of Multiple C2 and transmembrane domain-containing protein 2 could open doors to potential therapeutic strategies. Its involvement in cardiac outflow tract development positions it as a key target for research aimed at addressing congenital heart defects.